Phreesia, Inc. (NYSE:PHR) Receives $29.33 Consensus Price Target from Analysts

Phreesia, Inc. (NYSE:PHR) has earned a consensus recommendation of “Moderate Buy” from the twelve research firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $29.33.

Several equities research analysts recently issued reports on the stock. Truist Financial lifted their price target on shares of Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $23.00 target price on shares of Phreesia in a research report on Friday, September 27th. DA Davidson reissued a “buy” rating and issued a $32.00 price target on shares of Phreesia in a report on Thursday, September 5th. JMP Securities restated a “market outperform” rating and set a $30.00 price objective on shares of Phreesia in a report on Tuesday, December 10th. Finally, Robert W. Baird cut their target price on Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th.

Insider Activity

In related news, General Counsel Allison C. Hoffman sold 3,495 shares of the firm’s stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $24.88, for a total value of $86,955.60. Following the sale, the general counsel now owns 116,296 shares of the company’s stock, valued at approximately $2,893,444.48. This trade represents a 2.92 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Chaim Indig sold 3,089 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $21.03, for a total value of $64,961.67. Following the transaction, the chief executive officer now owns 1,220,647 shares of the company’s stock, valued at $25,670,206.41. This represents a 0.25 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 90,342 shares of company stock valued at $2,041,225. Company insiders own 5.80% of the company’s stock.

Institutional Trading of Phreesia

Large investors have recently modified their holdings of the company. International Assets Investment Management LLC grew its position in Phreesia by 2,179.7% in the 3rd quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock worth $33,000 after purchasing an additional 1,395 shares during the last quarter. nVerses Capital LLC grew its holdings in Phreesia by 76.5% in the 2nd quarter. nVerses Capital LLC now owns 3,000 shares of the company’s stock worth $64,000 after buying an additional 1,300 shares in the last quarter. Lombard Odier Asset Management USA Corp acquired a new stake in Phreesia in the 2nd quarter valued at approximately $202,000. Point72 DIFC Ltd bought a new stake in Phreesia during the 2nd quarter valued at $209,000. Finally, XTX Topco Ltd acquired a new position in Phreesia during the 3rd quarter worth $247,000. Institutional investors and hedge funds own 92.10% of the company’s stock.

Phreesia Price Performance

Shares of NYSE PHR opened at $25.76 on Friday. The company has a market capitalization of $1.50 billion, a price-to-earnings ratio of -17.52 and a beta of 0.98. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.77. Phreesia has a 1-year low of $17.07 and a 1-year high of $29.16. The business has a 50-day moving average of $21.30 and a 200-day moving average of $22.18.

Phreesia (NYSE:PHR) last released its quarterly earnings results on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. The firm had revenue of $106.80 million during the quarter, compared to analysts’ expectations of $106.33 million. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. Phreesia’s quarterly revenue was up 16.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.58) EPS. On average, equities analysts anticipate that Phreesia will post -1.16 EPS for the current fiscal year.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.